WEBULL

European Penny Stocks With Market Caps Under €300M

Simply Wall St · 07/28 05:04

The European market has been buoyed by optimism surrounding a potential EU-U.S. trade deal, with the pan-European STOXX Europe 600 Index seeing modest gains amid these developments. As investors navigate this landscape, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for growth at lower price points. Despite their vintage name, these stocks can still provide significant value when supported by strong financial health and solid fundamentals.

Top 10 Penny Stocks In Europe

Name Share Price Market Cap Rewards & Risks
Lucisano Media Group (BIT:LMG) €0.95 €14.11M ✅ 3 ⚠️ 4 View Analysis >
Maps (BIT:MAPS) €3.45 €45.82M ✅ 4 ⚠️ 2 View Analysis >
Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ✅ 4 ⚠️ 2 View Analysis >
IAMBA Arad (BVB:FERO) RON0.494 RON16.71M ✅ 2 ⚠️ 4 View Analysis >
Cellularline (BIT:CELL) €2.93 €61.8M ✅ 4 ⚠️ 2 View Analysis >
Libertas 7 (BME:LIB) €2.30 €49.01M ✅ 4 ⚠️ 4 View Analysis >
Bredband2 i Skandinavien (OM:BRE2) SEK3.255 SEK3.12B ✅ 4 ⚠️ 2 View Analysis >
Euroland Société anonyme (ENXTPA:ALERO) €3.26 €10.34M ✅ 2 ⚠️ 5 View Analysis >
Deceuninck (ENXTBR:DECB) €2.145 €296.15M ✅ 3 ⚠️ 1 View Analysis >
Netgem (ENXTPA:ALNTG) €0.97 €32.71M ✅ 4 ⚠️ 2 View Analysis >

Click here to see the full list of 335 stocks from our European Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Renta Corporación Real Estate (BME:REN)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Renta Corporación Real Estate, S.A. is a real estate company focused on acquiring, rehabilitating, and selling properties in Barcelona and Madrid, Spain, with a market cap of €24.80 million.

Operations: The company has not reported any specific revenue segments.

Market Cap: €24.8M

Renta Corporación Real Estate, S.A., with a market cap of €24.80 million, has shown resilience in its financial structure. The company's short-term assets exceed both its short and long-term liabilities, and its debt to equity ratio has improved significantly over the past five years from 112.9% to 25.9%. Although earnings have declined by an average of 15.7% annually over the past five years, recent results show a turnaround with net income rising to €2.36 million in H1 2025 despite reduced sales of €1.05 million compared to last year’s €6.07 million, indicating potential recovery prospects within the real estate sector in Spain's key markets.

BME:REN Financial Position Analysis as at Jul 2025
BME:REN Financial Position Analysis as at Jul 2025

Guillemot (ENXTPA:GUI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Guillemot Corporation S.A. designs, manufactures, and sells interactive entertainment equipment and accessories across various countries including France, Germany, and the United States, with a market capitalization of €74.88 million.

Operations: The company generates revenue from two main segments: Thrustmaster, which contributes €113.10 million, and Hercules, accounting for €12.02 million.

Market Cap: €74.88M

Guillemot Corporation S.A., with a market cap of €74.88 million, has a robust financial position, as its short-term assets (€110.9M) surpass both short and long-term liabilities. The company’s debt is well covered by operating cash flow (263%), and it holds more cash than total debt, reflecting prudent financial management. Recent governance changes saw Valentin Guillemot appointed CEO, potentially bringing fresh perspectives to the leadership team. Despite experiencing a large one-off loss of €4.4M in 2024, earnings are forecast to grow at 30.89% per year, suggesting optimism for future profitability improvements in its interactive entertainment segments.

ENXTPA:GUI Debt to Equity History and Analysis as at Jul 2025
ENXTPA:GUI Debt to Equity History and Analysis as at Jul 2025

Heidelberg Pharma (XTRA:HPHA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Heidelberg Pharma AG is a biopharmaceutical company specializing in oncology and antibody targeted amanitin conjugates (ATAC) with operations in Germany, the United States, and internationally, and has a market cap of €208.32 million.

Operations: The company's revenue is derived from its ADC Technology and Customer Specific Research segment, generating €4.18 million.

Market Cap: €208.32M

Heidelberg Pharma AG, with a market cap of €208.32 million, operates in the biopharmaceutical sector focusing on oncology. Despite being unprofitable and having limited revenue (€4.18 million), the company is debt-free and maintains a solid cash position, covering both short-term (€6.4M) and long-term liabilities (€37.6M). Recent developments include dosing the first patient in a Phase I clinical study for HDP-102 targeting non-Hodgkin lymphoma, demonstrating potential in its proprietary ATAC technology platform. However, earnings are forecast to decline by 11.4% annually over the next three years, highlighting ongoing financial challenges amidst promising R&D progress.

XTRA:HPHA Debt to Equity History and Analysis as at Jul 2025
XTRA:HPHA Debt to Equity History and Analysis as at Jul 2025

Summing It All Up

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.